APA (7th ed.) Citation

Thaçi, D., Ohtsuki, M., Maul, J., Szegedi, A., Luna, P. C., Lynde, C. W., . . . Papp, K. A. (2025). Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months. Dermatology & Therapy, 15(6), 1595. https://doi.org/10.1007/s13555-025-01420-3

Chicago Style (17th ed.) Citation

Thaçi, Diamant, et al. "Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months." Dermatology & Therapy 15, no. 6 (2025): 1595. https://doi.org/10.1007/s13555-025-01420-3.

MLA (9th ed.) Citation

Thaçi, Diamant, et al. "Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months." Dermatology & Therapy, vol. 15, no. 6, 2025, p. 1595, https://doi.org/10.1007/s13555-025-01420-3.